FDA OKs Trial of Investigational DM1 Therapy

FDA OKs Trial of Investigational DM1 Therapy

301530

FDA OKs Trial of Investigational DM1 Therapy

The U.S. Food and Drug Administration (FDA) has cleared Avidity Biosciences to start a Phase 1/2 clinical trial testing the company’s investigational therapy AOC 1001 in adults with myotonic dystrophy type 1 (DM1). “The FDA clearance to proceed with our Phase 1/2 clinical trial for AOC 1001 is a significant milestone for Avidity as we move into the clinic,” Sarah Boyce, president and CEO of Avidity, said in a press release. “We are continuing to…

You must be logged in to read/download the full post.